Muthiah Vaduganathan, MD, MPH, of Brigham and Women's discusses the barriers to preventing optimal prescribing practices for SGLT2 inhibitor and GLP-1 receptor agonist therapies.
Backed by data from a multitude of clinical trials released in recent years, SGLT2 inhibitors and GLP-1 receptor agonists have been the subject of discussion for specialists across multiple fields. In a recent scientific statement, the American Heart Association (AHA) outlined the apparent cardiorenal protection seen with the agents in major studies and also provided insight into determining which agent may be most appropriate for differing patient populations.
In the following interview, you will hear from Muthiah Vaduganathan, MD, MPH, a member of the writing committee for the aforementioned statement and a cardiologist at Brigham and Women’s Hospital. In the interview, Vaduganathan offers his perspective on why these classes of antidiabetes medications are under-prescribed despite the clearly defined benefit seen with either or both classes.